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Abdominal pain is one of the most fre-
quent reasons for consulting a doctor.
Despite it being a common clinical presen-
tation, abdominal pain remains a difficult
entity to treat. This is a result of multiple
factors including time course (i.e., acute
vs. chronic), etiology (e.g., inflammatory
vs. post-inflammatory), and stimulus (i.e.,
mechanical vs. chemical). About 10% of
the population suffer from chronic vis-
ceral pain in the form of irritable bowel
syndrome (IBS), many of which go undi-
agnosed. They are hypersensitive to con-
traction and distension of the gut (Barbara
et al., 2011; Keszthelyi et al., 2012), but the
pathophysiology of pain is poorly under-
stood. While the intestinal epithelium is
a site of high metabolic activity, includ-
ing digestion/absorption, secretion, hor-
mone release, and immune interactions, it
is generally not viewed as a site of pain
modulation. However, there are numer-
ous factors at the level of the epithelium
capable of modulating pain. This article
will highlight the potential role of these
factors in nociceptive signaling to identify
new therapeutic targets.
NOCICEPTIVE INNERVATION OF THE
GUT
Like in other regions of the body and
internal organs, the identification of which
gastrointestinal primary afferent neurons
transmit signals giving rise to pain relies
on classification according to their ade-
quate stimuli. It is well-known that cutting
and burning of the gut is not necessar-
ily perceived as painful, but generation of
intense force by distension or contraction
normally is (Cervero, 1994). In the dis-
eased gut less intense forces are required
(Coutinho et al., 1996). Therefore, a gut
nociceptor is defined for the purposes of
this article as a primary afferent fiber that
has a high threshold to mechanical stimuli
in the healthy gut. They usually also
respond directly to inflammatory media-
tors (Blackshaw et al., 2007). A number
of investigations over the last five decades
have shown these to innervate blood ves-
sels either within or outside the gut wall
(Bessou and Perl, 1966; Blumberg et al.,
1983; Song et al., 2009). They are there-
fore a form of vascular endings, whereas
low-threshold afferents innervate the mus-
cle layers of the gut wall or the villi of the
mucosa (Brookes et al., 2013). An excep-
tion to this rule may well be esophageal
afferents which may transmit pain directly
from the squamous epithelium in response
to acid (which may reflux from the stom-
ach) (Bhat and Bielefeldt, 2006). In the
abdominal viscera, it makes sense to place
nociceptive endings on blood vessels, since
these are less likely to be exposed to
mechanical force than those in smooth
muscle, and would serve an alarm func-
tion for impending dangerous events like
rupture or bleeding of the gut. In general,
nociceptive afferents innervate the gut via
the splanchnic nerves, or in the esophagus
via the thoracic sympathetic nerves. There
are also sub-populations that innervate
via the pelvic and vagal parasympathetic
pathways in the rectum and esophagus,
respectively.
Whether or not visceral nociceptors dif-
fer from those in the rest of the body
is controversial, but there are accounts
of differing gene expression between the
two systems, e.g., Brierley et al. (2008).
Another important issue is how nocicep-
tors change in disease states, which may
change the way we define them. It is
clear from a number of studies that their
mechanical thresholds are substantially
reduced during inflammation and after
healing, so that they respond within the
physiological range of stimuli (Jones et al.,
2005). In fact Hughes et al found that only
nociceptors became markedly sensitized
after recovery from inflammation, in both
pelvic and splanchnic pathways, whereas
other types of afferent fibers were affected
little or not at all (Hughes et al., 2009).
The central endings of visceral afferents
are most commonly found in the dor-
sal horn of the spinal cord, where they
synapse on projection neurons that send
axons to pain processing areas of the brain
(Honoré et al., 2002). The dorsal horn is
a site of major modulation of pain sig-
nals which can override or exacerbate the
peripheral signal. Another major site of
modulation that is emerging is at the site
of signal generation in peripheral endings
by a number of endogenous factors. These
may be derived from enterocytes, the most
numerous cells in the epithelium, or from
more specialized cells such as enteroen-
docrine or immune cells. The examples
given below are the best we can find cur-
rently and represent derivatives from these
three cell types, respectively.
CYCLIC-GUANOSINE-3′,5′-
MONOPHOSPHATE
(cGMP)
Recently it has been demonstrated that
stimulation of guanylate-cyclase C (GC-C)
on epithelial cells causes release of cGMP
(Blackshaw and Brierley, 2013). This
extracellular cGMP inhibits nociceptors in
the colon and rectum (Castro et al., 2013;
Feng et al., 2013). This is believed to be
a mechanism by which linaclotide, a GC-
C agonist, alleviates pain in patients with
IBS constipation subtype. Demonstration
of this epithelial-afferent anti-nociceptive
signaling raises the possibility that other
mediators released from epithelial cells can
inhibit painful signals arising from the gut.
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GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
GLP-1 is an incretin located within
enteroendocrine L-cells of the intestine
that is released upon food intake (Punjabi
et al., 2011). It plays an important role
in postprandial glucose homeostasis and
can alter gastrointestinal (GI) motility
(Näslund et al., 1999; Hellström et al.,
2008; Edholm et al., 2009; Punjabi et al.,
2011). Interestingly, in a phase II trial of
IBS patients the GLP-1 analog ROSE-010
reduced acute exacerbations of abdomi-
nal pain compared to placebo (Hellström
et al., 2009). Whether this analgesic effect
was a primary effect on afferent fibers
innervating the gut or secondary to a
reduction in dysmotility could not be
determined. It has been shown that GLP-1
can directly activate vagal afferents within
the upper GI tract (Gaisano et al., 2010).
However, the expression of GLP-1 is great-
est in the distal GI tract. Taken together,
this raises an intriguing possibility that
release of GLP-1 from L-cells in the distal
gut may inhibit spinal afferents respon-
sible for nociceptive transmission. Many
treatments for type 2 diabetes are aimed
at augmentation of the action of GLP-1
on the endocrine pancreas to boost insulin
release. It would be interesting to deter-
mine if these treatments have a paral-
lel effect on visceral pain, although this
may be small since the effect of GLP-1
on afferent fibers is probably a paracrine
effect whereas GLP-1 mimetics augment
endocrine actions.
SOMATOSTATIN
There are other epithelial derived medi-
ators with more prominent roles in the
upper GI tract that may be capable of
inhibiting visceral pain. Somatostatin is
found in a variety of cell types in the
gut including D-cells in the gut mucosa
(Patel, 1999). Its role is largely inhibitory
of a number of physiological functions
within the GI tract including secretion
and motility (Patel, 1999). There is also
evidence that it can inhibit visceral per-
ception. Somatostatin receptor agonists
reduced afferent firing in “wide-dynamic
range” fibers, which would be expected
to transmit noxious stimuli (Booth et al.,
2001). Jejunal afferents in knockout mice
lacking the somatostatin receptor sst2 had
augmented responses to both low and high
threshold distension as well as chemical
stimulation suggesting a tonic inhibitory
role of somatostatin in visceral sensi-
tivity (Rong et al., 2007). Conversely,
in recordings from pelvic afferents in
rats, the somatostatin receptor agonist
octreotide appeared to reduce visceral
pain via a central mechanism rather
than at the peripheral site (Su et al.,
2001). Interestingly, octreotide inhibited
sensation to rectal balloon distension in
both healthy volunteers and IBS patients
(Hasler et al., 1993, 1994). The investi-
gators believed this was likely due to a
peripheral action of octreotide as previous
work strongly suggested that octreotide
peripherally inhibited cerebral and spinal
electrical potentials after electrical stimu-
lation of the rectum (Chey et al., 1995;
Schwetz et al., 2004). These contrasting
findings suggest that somatostatinmay sig-
nal to specific afferent subtypes and/or
there are species differences. Therefore,
further investigations of an inhibitory role
of somatostatin on visceral nociception in
the distal gut are needed.
GALANIN
Galanin is an important neuromodula-
tor in the enteric nervous system, which
acts on three types of G-protein cou-
pled receptor—GAL1, 2, and 3, which
are inhibitory, excitatory, and inhibitory
respectively. GAL1 and 2 have corre-
sponding effects on mechanosensitivity of
vagal afferents at low concentrations (Page
et al., 2007), and may indeed have an
effect endogenously, but we have only pre-
liminary unpublished data indicating an
inhibitory effect of galanin on spinal affer-
ents. It is clear that galanin may have
potent central effects on pain processing,
especially in neuropathic and inflamma-
tory pain (Wynick et al., 2001), but this
peripheral action in the gut is unexplored.
OPIOIDS
T-lymphocytes contain and release beta-
endorphin, which activates the mu opi-
oid receptor. This is considered to be an
important mechanism of endogenous pain
relief, and part of the action of exogenous
opioids given therapeutically. We recently
showed this is also the case for the gut,
where these cells migrate into the tissue
and inhibit the response of nociceptors to
mechanical stimuli (Hughes et al., 2013b).
However, T-cells also release interleukins
and other cytokines that can augment the
sensitivity of nociceptors or even activate
them directly, so there is a balance of
excitatory and inhibitory immune modu-
lation of peripheral nociceptive signaling.
It is not known if stimuli to the gut in
health or disease can preferentially evoke
release of opioids or other mediators from
white cells, but this would provide a con-
venient means of pain suppression during
normal digestion.
In addition to mu receptors, visceral
afferents also express kappa opioid recep-
tors, for which the natural ligand is dynor-
phin, although it is unclear if endogenous
dynorphin plays a role in peripheral pain
modulation. However, it has been known
for some time that kappa opioid recep-
tor agonists reduce activation of colorectal
afferents by distension, and correspond-
ingly pain behaviors evoked in conscious
animals (Gebhart et al., 2000). Recent data
indicates that visceral nociceptors increase
their expression of kappa receptors in a
model of chronic visceral hypersensitivity
(Hughes et al., 2013a), and correspond-
ingly their inhibition by kappa agonists.
This probably underlies the clinical effi-
cacy of kappa ligands on pain in mod-
erate to severe IBS (Mangel and Hicks,
2012).
CONCLUSIONS
In addition to the scope formany interven-
tions that could reduce visceral pain in the
clinic targeted at inhibitory mechanisms,
there are also many sources of endogenous
inhibitors, only some of which have been
explored. It is clear nutrients, microbiota
and other immunomodulatory influences
may impact on the behavior of nocicep-
tors, for example by releasing enteroen-
docrine mediators or immune-derived
mediators. In the case of microbiota, there
is also the possibility of direct actions of
microbial products on sensory endings,
as has already been shown to occur else-
where in the nervous system (Hsiao et al.,
2013).
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